SCHEMBL1934595

SCHEMBL1934595

NC(=O)OCc1ccc(CO)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ PRSS1 P07477 1/20 0.43
▸ PRSS2 P07478 1/20 0.43
▸ PRSS3 P35030 1/20 0.43
▸ CA2 P00918 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA4 P22748 1/20 0.42
▸ CA6 P23280 1/20 0.42
▸ CA5A P35218 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ CA5B Q9Y2D0 1/20 0.42
▸ PARP10 Q53GL7 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 2/20 0.40
▸ HCAR2 Q8TDS4 1/20 0.40
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30437401 0.91 KMT2A (0.50) KMT2AMEN1CA2PARP10ALDH1A1
SCHEMBL143772 0.84 MEN1 (0.61) KMT2AMEN1CA2CA12CA4
SCHEMBL5709288 0.83 TPSAB1 (0.51) KMT2AMEN1PRSS1PARP10ALDH1A1
SCHEMBL147245 0.83 KMT2A (0.44) KMT2AMEN1PARP10ALDH1A1LMNA
SCHEMBL2756749 0.82 KMT2A (0.47) KMT2AMEN1CA2CA12CA1
SCHEMBL113937 0.81 IDO1 (0.54) KMT2AMEN1CA2CA1CA9
SCHEMBL2297635 0.81 PARP10 (0.54) CA2CA1CA9PARP10ALDH1A1
SCHEMBL21385042 0.81 KMT2A (0.42) KMT2AMEN1CA2CA1PARP10
SCHEMBL436380 0.81 KMT2A (0.42) KMT2AMEN1PRSS1CA2PARP10
SCHEMBL5762294 0.81 MAOB (0.54) KMT2AMEN1PARP10ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113521299-B Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof 江苏恒瑞医药股份有限公司 2024-07-16 — — CN disclosed
CN-118019750-A Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2024-05-10 — — CN disclosed
CN-117838875-A Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2024-04-09 — — CN disclosed
CN-115867319-B Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2024-01-02 — — CN disclosed
WO-2023091957-A1 PEPTIDE CONJUGATES OF PEPTIDIC TUBULIN INHIBITORS AS THERAPEUTICS CYBREXA 4, INC. (US) 2023-05-25 — — WO disclosed
CN-115867319-A Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2023-03-28 — — CN disclosed
CN-114222590-A Compositions, devices and methods for factor VII therapy 西吉隆医疗股份有限公司 2022-03-22 — — CN disclosed
CN-113840620-A Compositions, devices and methods for treating fabry disease 西吉隆医疗股份有限公司 2021-12-24 — — CN disclosed
CN-113521299-A Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof 江苏恒瑞医药股份有限公司 2021-10-22 — — CN disclosed
CN-112203646-A Implantable particles and related methods 西吉隆医疗股份有限公司 2021-01-08 — — CN disclosed
CN-112105612-A Anti-fibrotic compounds, devices and uses thereof 西吉隆医疗股份有限公司 2020-12-18 — — CN disclosed
CN-111372612-A Methods, compositions, and implantable elements comprising viable cells 西吉隆医疗股份有限公司 2020-07-03 — — CN disclosed
CN-110545814-A Chemokine CXCR4 receptor modulators and uses related thereto UNIV EMORY 2019-12-06 — — CN disclosed
EP-2331518-A1 NEW BRADYKININ B1 ANTAGONISTS Evotec AG (DE) 2011-06-15 — — EP disclosed
WO-2010020556-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC NEUROSCIENCES GMBH (DE) 2010-02-25 — — WO disclosed
Send feedback